Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Home Print this page Email this page Small font size Default font size Increase font size Users Online: 400


 
  Table of Contents  
EDITORIAL
Year : 2012  |  Volume : 18  |  Issue : 1  |  Page : 1  

Tranexamic acid: A recipe for saving lives in traumatic bleeding


Clinical Trials Unit, Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, United Kingdom

Date of Web Publication30-Apr-2012

Correspondence Address:
Ian Roberts
Clinical Trials Unit, Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT
United Kingdom
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/1117-6806.95463

Rights and Permissions

How to cite this article:
Roberts I. Tranexamic acid: A recipe for saving lives in traumatic bleeding. Niger J Surg 2012;18:1

How to cite this URL:
Roberts I. Tranexamic acid: A recipe for saving lives in traumatic bleeding. Niger J Surg [serial online] 2012 [cited 2019 Sep 16];18:1. Available from: http://www.nigerianjsurg.com/text.asp?2012/18/1/1/95463

Using kitchen scales, carefully weight out 4 kilograms of rice and pour it into a deep saucepan. Now put your hands into the rice and let the grains run between your fingers. Contemplate carefully each grain. The number of grains (about 140,000) is approximately the number of lives that could be saved each year world-wide if all hospitalized trauma patients with significant bleeding were treated with tranexamic acid (TXA) within 3 hours of injury. TXA is cheap and widely available. All that is needed to reap these human benefits is that doctors use it.

That TXA is a potent inhibitor of fibrinolysis was first reported by Shosuke and Utako Okamoto in The Keio Journal of Medicine in September 1962. [1] Since then TXA has been widely used to treat heavy menstrual bleeding and to reduce blood loss in elective surgery where it reduces blood transfusion by about one third. [2] The CRASH-2 collaborators hypothesized that TXA might also reduce bleeding in trauma patients. The CRASH-2 trial was a UK government funded randomized trial of the effects of the early administration of TXA on death, vascular occlusive events and blood transfusion in bleeding trauma patients. A total of 20,211 adults with significant traumatic bleeding were randomized to receive TXA or matching placebo, with 99.6% follow-up. The risk of death due to bleeding was significantly reduced with TXA. If TXA is given within three hours of injury, it reduces the risk of bleeding to death by nearly one third (relative risk= 0.72 [95% CI 0.63-0.83], P<0.001). All cause mortality was also significantly reduced. [3],[4] The large numbers of patients studied in a wide range of different health care settings help these results to be generalized widely. On the basis of the results of the CRASH-2 trial, TXA has been included in the WHO list of essential medicines. [5] Giving TXA to bleeding trauma patients within three hours of the injury could save over 100,000 lives per year world-wide. Giving TXA to bleeding trauma patients is highly cost effective in high, middle and low income countries. [6] It is essential that all doctors who treat trauma patients are aware of the results of the CRASH-2 trial.

TXA should be given to all adults with significant haemorrhage (SBP < 90, HR > 110) or those considered by the clinician to be at risk for significant haemorrhage. Because the effect of tranexamic acid on death due to bleeding depends importantly on the time interval between the injury and the onset of treatment it should be given as early as possible and within 3 or 4 hours of the injury as it is unlikely to be effective if given later than this.

 
  References Top

1.Okamoto S, Okamoto U. Amino-Methyl-Cyclohexane-Carbolic Acid: AMCHA. A New Potent Inhibitor of Fibrinolysis. Keio J Med 1962;11:105-15.  Back to cited text no. 1
    
2.Henry DA, Carless PA, Moxey AJ, O'Connell D, Stokes BJ, McClelland B, et al. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2007;4:CD001886.  Back to cited text no. 2
[PUBMED]  [FULLTEXT]  
3.CRASH-2 trial collaborators, Shakur H, Roberts I, Bautista R, Caballero J, Coats T, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomized, placebo-controlled trial. Lancet 2010;376:23-32.   Back to cited text no. 3
[PUBMED]  [FULLTEXT]  
4.CRASH-2 collaborators, Roberts I, Shakur H, Afolabi A, Brohi K, Coats T, et al. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomized controlled trial. Lancet 2011;377:1096-101.  Back to cited text no. 4
[PUBMED]  [FULLTEXT]  
5.Available from: http://www.who.int/selection_medicines/committees/expert/18/en/index.html. [Last accessed on 15 March, 2012.  Back to cited text no. 5
    
6.Guerriero C, Cairns J, Perel P, Shakur H, Roberts I; CRASH 2 trial collaborators. Cost-effectiveness analysis of administering tranexamic acid to bleeding trauma patients using evidence from the CRASH-2 trial. PLoS One 2011;6:e18987.  Back to cited text no. 6
[PUBMED]  [FULLTEXT]  




 

Top
   
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
References

 Article Access Statistics
    Viewed1903    
    Printed180    
    Emailed0    
    PDF Downloaded125    
    Comments [Add]    

Recommend this journal